Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.
Kötter
Ina
I
University Hospital, Department of Internal Medicine II (Haematology, Oncology, Immunology, Rheumatology), Tübingen, Germany.
Zierhut
Manfred
M
Eckstein
Anja
A
Vonthein
Reinhard
R
Ness
Thomas
T
Günaydin
Ilhan
I
Grimbacher
Bodo
B
Blaschke
Sabine
S
Peter
Hans-Hartmut
HH
Kanz
Lothar
L
Stübiger
Nicole
N
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011994:Recombinant Proteins; D031300:Retinal Vasculitis / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome; D014606:Uveitis, Anterior / Q000188:drug therapy* / Q000209:etiology; D015866:Uveitis, Posterior / Q000188:drug therapy* / Q000209:etiology; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins